Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...
'There has never been a more dangerous time to take drugs': The rising global threat of nitazenes and synthetic opioids
In the early hours of September 14, 2021, three men parked in a quiet car park in the southern English market town of ...